Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Quisinostat - Janssen Pharmaceutica/NewVac

Next Previous
Drug Profile

Quisinostat - Janssen Pharmaceutica/NewVac

Alternative Names: JNJ-26481585

Latest Information Update: 28 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Johnson & Johnson Pharmaceutical Research & Development
  • Developer Janssen Pharmaceutica; Janssen Research & Development; NewVac
  • Class Antineoplastics; Hydroxy acids; Hydroxylamines; Piperidines; Small molecules
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Lung cancer; Ovarian cancer; Uveal melanoma
  • No development reported Breast cancer; Pulmonary arterial hypertension; Sarcoma
  • Discontinued Cutaneous T-cell lymphoma; Leukaemia; Multiple myeloma; Myelodysplastic syndromes; Solid tumours

Most Recent Events

  • 28 Dec 2025 No recent reports of development identified for preclinical development in Pulmonary-arterial-hypertension in USA
  • 08 May 2025 Phase-II clinical trials in Uveal melanoma (Second-line therapy or greater) in USA (PO) (NCT06932757)
  • 17 Apr 2025 University of Miami plans a phase II trial in Uveal Melanoma (Second-line therapy or greater) in USA (PO) in June 2025 (NCT06932757)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top